Life Sciences Funding in Europe (2006)- Phase I - Biologics Market Research

Life Sciences Funding in Europe (2006)- Phase I
Published Date: November 2006
Published By: Frost & Sullivan
Order Code: R1-5147
Price: $6500 Electronic Access - Single User
$8000 Electronic Delivery - Global Site License
$7000 Hard Copy Mail Delivery

Research Overview
This Frost & Sullivan research service entitled Life Sciences Funding in Europe (2006) - Phase I provides an overview of the current funding scenario and budget allocations of various funding bodies in the United Kingdom, Germany and France, along with a complete analysis of key challenges and trends prevailing in the European scientific landscape. It also provides a comparative year-to-year analysis of specific data points in funding. In this research service, Frost & Sullivan's expert analysts thoroughly examine the following markets: the United Kingdom, Germany and France.
Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
By Geographic Region
The United Kingdom
Germany
France
Market Overview
FP6 Driving Strong Research Efforts in Life Sciences and Biotechnology in Europe
Public interest in and acceptance of the scientific revolution have increased considerably in recent years in Europe, with Europeans showing heightened optimism about the direction and potential outcomes of life science and biotechnology research. Advancements in these areas have immense potential in a multitude of healthcare applications as well as in stimulating economic growth. "Life sciences and biotechnology hold promising and tangible societal and economic benefits," notes the analyst of this research service. "Europe possesses the scientific base, but the framework to harness this potential is essential." Thus, the need to support intensive research in these high-potential areas led to the implementation of the Sixth Framework Programme (FP6), which aims to accelerate technological developments in biological sciences in the post-genomic era and ultimately improve human health.
FP6 represents a concerted effort to create a strong European research arena within which policies are framed to enable better integration of research capabilities. It has a distinct focus on life sciences, genomics and biotechnology. In fact, life sciences funding forms one of the seven thematic priorities in the FP6, attracting funding of 2,264 million euros during 2003 to 2006. Funding allocation for major research areas such as genomic research through FP6 also saw a steady increase from 67.0 per cent in 2003 to 73.0 per cent in 2005. Within the genomics area, substantial funding was allotted to the research of new drugs, diagnostics and new therapies, all of which indicate a positive trend for the future.
Move towards Making Europe a Knowledge-Based Economy Faces Various Challenges
Exceptional advances in basic life sciences research in recent years such as the human genome project are poised to considerably increase European funding for this area. However, the current life sciences funding landscape faces several challenges. Key among these is the need to strategise and implement research policies and effectively utilise the funds allotted to specific projects in Europe. Improper consolidation and chanelling of various public funds is a major issue in life science funding at present.
Considering that there are numerous funding organisations in place including public funding, intergovernmental organisations, charities, non-profit organisations and the European commission, efficiently integrating these various funds is likely to be a huge task. "Efficient utilisation of funds and greater public involvement are of critical importance," says the analyst. "A constructive political and societal collaboration is vital to increase the involvement of public investment for basic research in Europe." Investing in advanced infrastructure that caters to the needs of scientists is another critical factor in expanding the scale of European life sciences research.